An interventional study of Interposition supraciliary implant in Glaucoma, Open-Angle, sponsored by Ciliatech. Terminated at 1 site in France. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-12-20.
Sponsored by Ciliatech · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the safety and effectiveness of a novel interposition supraciliary implant as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at least one class of topical medical therapy
68 patients will be included in this 5 years interventional study. All patients shall be indicated for glaucoma surgery alone (not combined with cataract), and will undergo incisional glaucoma therapy, including a novel simplified surgical technique allowing placement of an interposition supraciliary permanent device.
Several patient data like IOP, visual capacity or associated pharmacological treatments will be recorded pre and post-operatively all along the follow-up.
Purpose is to ensure device safety, and verify IOP and associated pharmacological treatment reduction after surgery, and evolution along follow-up.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 27 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Ciliatech is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Any patients corresponding to inclusion / exclusion criteria
Device: Interposition supraciliary implant
Surgical placement of an interposition supraciliary implant in the supraciliary space
Assess post-op IOP reduction
Proportion of Eyes With Intraocular Pressure (IOP) Reduction of ≥ 20%
Time frame: 6 months
Assess post-op IOP clinical success
Proportion of Eyes With Intraocular Pressure (IOP) \< 21 mmHg
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ciliatech